Grünenthal Bolsters US Portfolio With Buyout Of Valinor

 
• By Joseph Haas
  
Grünenthal is acquiring Valinor to get US rights to OIC drug Movantik • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business